Results for tag: "Focal Segmental Glomerulosclerosis Drugs"

The Focal Segmental Glomerulosclerosis (FSGS) drugs market is a niche segment within the broader scope of liver and kidney disorders pharmaceuticals. FSGS is a disease that affects the kidney's filtering units, known as glomeruli, causing them to become scarred and lose functionality. As a result, it is part of a larger category of diseases classified as glomerular diseases, which can lead to nephrotic syndrome and ultimately, chronic kidney disease. Drug therapies for FSGS are designed to reduce proteinuria (excess protein in urine) and preserve kidney function for as long as possible. Current treatment options may include corticosteroids, immunosuppressants, and certain blood pressure-lowering drugs, which are also employed to address other kidney and liver disorders involving immune-mediated and inflammatory processes. There are several companies active in the FSGS drugs market. Prominent pharmaceutical firms include Pfizer, Novartis, and Bristol-Myers Squibb, which have a robust portfolio of drugs catering to various renal and hepatic conditions, including treatments suitable for FSGS. Smaller specialized biotech companies such as Retrophin (now Travere Therapeutics) and Variant Pharmaceuticals also concentrate efforts on innovative therapeutics targeting rare kidney disorders like FSGS. These companies are typically involved in the research and development of new drugs, with some having medications in clinical trials specifically aimed at treating FSGS. Show Less Read more